Photo credit: www.investing.com
Investor Alert: Class Action Regarding Applied Therapeutics Securities
New York, New York–Rosen Law Firm, a prominent global firm dedicated to investor rights, has issued a reminder for individuals who purchased securities of Applied Therapeutics, Inc. (NASDAQ: ATXI) between January 3, 2024, and December 2, 2024. The law firm emphasizes that the deadline to apply to be a lead plaintiff in this class action is approaching on February 18, 2025.
Eligibility and Compensation Potential
Investors who acquired Applied Therapeutics securities during the specified class period may be entitled to financial compensation without any upfront costs, thanks to a contingency fee structure. This arrangement allows affected investors to pursue claims without the burden of direct legal expenses.
Next Steps for Interested Investors
To become part of the class action against Applied Therapeutics, individuals can visit this link or contact Phillip Kim, Esq. via a toll-free number at 866-767-3653, or by emailing case@rosenlegal.com. It is important to note that a formal class action lawsuit has already been initiated. Interested parties who wish to serve as lead plaintiff must submit their motion to the court before the deadline of February 18, 2025. The lead plaintiff acts on behalf of all class members in the litigation process.
Why Choose Rosen Law Firm?
Rosen Law Firm encourages investors to select legal representation with proven success in securities class actions. Many firms that broadcast such notices lack the experience and resources necessary for effective litigation and may simply serve as intermediaries. Rosen Law Firm’s accolades include having secured the largest settlement from a securities class action against a Chinese company at its time and consistently ranking among the top firms in securities class action settlements since 2013. The firm has recovered substantial amounts for investors, including over $438 million in 2019 alone. Founding partner Laurence Rosen has received notable recognition in the legal field, and several attorneys at the firm have been acknowledged by Lawdragon and Super Lawyers for their expertise.
Allegations Against Applied Therapeutics
The lawsuit claims that statements made by Applied Therapeutics during the class period were misleading, as they obscured critical details surrounding the company’s clinical trial protocols and practices. Investors were led to believe that proper protocols were being followed, when in fact, the company allegedly was not adhering to necessary standards. This failure to comply with established clinical practices posed significant risks, particularly concerning the potential rejection of trial data by the U.S. Food and Drug Administration (FDA) during the New Drug Application process. Upon learning the true circumstances, investors reportedly experienced damages.
Participating in the Class Action
To learn more about joining the class action or to express interest, please visit this page, or reach out to Phillip Kim, Esq. at the toll-free number provided earlier.
It is important to note that a class has not yet been certified. Until such a certification occurs, investors are not represented by counsel unless they choose to retain legal representation themselves. Investors may opt to remain as absent class members and can choose not to take any action at this stage. Participation as a lead plaintiff is not required for investors who want to potentially benefit from any future recovery.
Stay Updated
For the latest updates, follow Rosen Law Firm on LinkedIn, Twitter, and Facebook.
Source
www.investing.com